Drug company-sponsored patient assistance programs: A viable safety net?

Niteesh K. Choudhry, Joy L. Lee, Jessica Agnew-Blais, Colleen Corcoran, William H. Shrank

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Drug company-sponsored patient assistance programs (PAPs) provide access to brand-name medications at little or no cost and have been advocated as a safety net for inadequately insured patients. Yet little is known about these programs. We surveyed drug company-sponsored PAPs and found much variability in their structures and application processes. Most cover one or two drugs. Only 4 percent disclosed how many patients they had directly helped, and half would not disclose their income eligibility criteria. A better understanding of PAPs might clarify their role in improving access to medications, the adequacy of existing public programs, and their impact on cost-effective medication use.

Original languageEnglish (US)
Pages (from-to)827-834
Number of pages8
JournalHealth Affairs
Volume28
Issue number3
DOIs
StatePublished - May 2009
Externally publishedYes

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Drug company-sponsored patient assistance programs: A viable safety net?'. Together they form a unique fingerprint.

  • Cite this